

# Amelia A Langston

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7491569/publications.pdf>

Version: 2024-02-01

75  
papers

1,511  
citations

567144

15  
h-index

330025

37  
g-index

76  
all docs

76  
docs citations

76  
times ranked

2530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation. <i>Blood Advances</i> , 2022, 6, 746-749.	2.5	18
2	Why does the place where the allogeneic transplant patient calls home matter?. <i>Cancer</i> , 2021, 127, 510-511.	2.0	0
3	Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e497-e505.	1.4	14
4	Human Adenovirus 11 in 2 Renal Transplant Recipients: Suspected Donor-Derived Infection. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab092.	0.4	3
5	Pure red blood cell aplasia: patient management pitfalls in major ABO-incompatible haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 193, 701-702.	1.2	1
6	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021, 39, 1865-1877.	0.8	111
7	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	0.6	124
8	Cytomegalovirus immunoglobulin G: passive transfer or prior infection?. <i>British Journal of Haematology</i> , 2021, 195, 11-12.	1.2	0
9	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	2.5	24
10	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	0.6	0
11	Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8 <sup>+</sup> T cells drive gastrointestinal acute graft-versus-host disease. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	39
12	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020, 126, 1235-1242.	2.0	8
13	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
14	Potent Interaction between CMV Reactivation and Gvhd: Immunologic Evidence for Blunting of CMV-Driven Immune Reconstitution in the Setting of Gvhd. <i>Blood</i> , 2020, 136, 50-50.	0.6	1
15	Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic Gvhd. <i>Blood</i> , 2020, 136, 38-39.	0.6	0
16	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10
17	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haematopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	2.2	84
18	Safety and survival outcomes for bloodless transplantation in patients with myeloma. <i>Cancer</i> , 2019, 125, 185-193.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Transcriptomic Analysis of CD4+ T Cell Dysfunction during Gvhd: Evidence for Profound Reprograming of T Cell Signaling during Acute Gvhd That Is Controlled during CD28:CD80/86 Costimulation Blockade with Abatacept. <i>Blood</i> , 2019, 134, 596-596.	0.6	0
20	Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 973-982.	2.0	18
21	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	2.0	44
22	Myeloablative busulfan/cytosan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 837-843.	0.6	10
23	Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 1443-1453.	0.8	248
24	Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 3043-3054.	0.8	357
25	Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4118.	1.8	7
26	Antimicrobial Stewardship in the Hematopoietic Stem Cell Transplant Population. <i>Current Treatment Options in Infectious Diseases</i> , 2018, 10, 249-262.	0.8	1
27	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018, 132, 5911-5911.	0.6	1
28	Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?. <i>Cancer</i> , 2017, 123, 2482-2488.	2.0	12
29	Risk factors and epidemiology of <i>Clostridium difficile</i> infection in hematopoietic stem cell transplant recipients during the peritransplant period. <i>Transplant Infectious Disease</i> , 2017, 19, e12649.	0.7	18
30	Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S96-S99.	0.2	3
31	Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. <i>Hematology Reports</i> , 2017, 9, 7083.	0.3	3
32	Opportunity for Collaboration Between Radiation Injury Treatment Network Centers and Medical Toxicology Specialists. <i>Southern Medical Journal</i> , 2017, 110, 497-501.	0.3	3
33	Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital. <i>Journal of Stem Cell Research &amp; Therapy</i> , 2016, 06, .	0.3	3
34	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 466-471.e1.	0.2	37
35	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	1.2	12
36	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	2.0	27

#	ARTICLE	IF	CITATIONS
37	79: Improving Test Utilization for Chimerism Analysis After Hematopoietic Stem Cell Transplantation. American Journal of Clinical Pathology, 2015, 143, A048-A048.	0.4	0
38	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 514-518.	0.2	4
39	Optimal Dosing of Melphalan As High-Dose Therapy Before Autologous Hematopoietic Stem Cell Transplantation in Myeloma Patients With Solitary Kidney: A Case Series. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e59-e63.	0.2	3
40	Dermato-Neuro Syndrome in a Patient Treated With Autologous Stem Cell Transplant for Scleromyxedema. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e213-e215.	0.2	11
41	Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 852-857.	2.0	29
42	Similar Survival for Patients Undergoing Reduced-Intensity Total Body Irradiation (TBI) Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leukemia. International Journal of Radiation Oncology Biology Physics, 2014, 89, 360-369.	0.4	7
43	Incidence and Geographic Distribution of Adult Acute Leukemia in the State of Georgia. Southern Medical Journal, 2014, 107, 497-500.	0.3	3
44	In Vivo T Cell Costimulation Blockade with Abatacept for Acute Graft-versus-Host Disease Prevention: A First-in-Disease Trial. Biology of Blood and Marrow Transplantation, 2013, 19, 1638-1649.	2.0	96
45	Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT). Blood, 2013, 122, 5606-5606.	0.6	0
46	Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample. Blood, 2013, 122, 5582-5582.	0.6	0
47	A First-in-Disease Trial of in Vivo Costimulation Blockade for Acute GvHD Prevention: The Addition of Abatacept to Standard GvHD Prophylaxis Controls Early CD4+ T Cell Proliferation and Is Associated with Low Rates of Severe Acute GvHD. Blood, 2012, 120, 741-741.	0.6	1
48	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs). Blood, 2011, 118, 3994-3994.	0.6	5
49	A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials. Blood, 2011, 118, 3954-3954.	0.6	0
50	Post-Transplant Platelet Recovery Kinetics and Its Association with Overall Survival in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT). Blood, 2011, 118, 2049-2049.	0.6	0
51	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. Blood, 2011, 118, 1959-1959.	0.6	0
52	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. Blood, 2011, 118, 2988-2988.	0.6	5
53	CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial. Blood, 2011, 118, 4078-4078.	0.6	0
54	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables. Blood, 2010, 116, 3450-3450.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Use of posaconazole in the treatment of invasive fungal infections. Expert Review of Hematology, 2009, 2, 619-630.	1.0	10
56	A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.. Blood, 2009, 114, 2047-2047.	0.6	1
57	Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.. Blood, 2009, 114, 1165-1165.	0.6	0
58	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. Blood, 2008, 112, 3332-3332.	0.6	2
59	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. Blood, 2008, 112, 3644-3644.	0.6	0
60	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. Blood, 2008, 112, 1183-1183.	0.6	0
61	The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.. Blood, 2007, 110, 1912-1912.	0.6	0
62	T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT).. Blood, 2006, 108, 3224-3224.	0.6	1
63	Cost-Effectiveness of Posaconazole Versus Standard Azole Therapy in the Prevention of Invasive Fungal Infections among High-Risk Neutropenic Patients in the U.S.. Blood, 2006, 108, 3311-3311.	0.6	1
64	Deep Venous Thromboses Associated with Peripherally Inserted Central Catheters in Patients with Hematological Malignancies.. Blood, 2006, 108, 4587-4587.	0.6	0
65	Infliximab for the Treatment of Chronic Graft Versus Host Disease.. Blood, 2006, 108, 2889-2889.	0.6	0
66	Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.. Blood, 2006, 108, 1960-1960.	0.6	0
67	Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.. Blood, 2006, 108, 3065-3065.	0.6	0
68	Patient Characteristics in CD 20+ and CD 20 <sup>+</sup> Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis.. Blood, 2005, 106, 4523-4523.	0.6	0
69	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. Blood, 2005, 106, 4634-4634.	0.6	0
70	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. Blood, 2005, 106, 2016-2016.	0.6	0
71	Prognostic Significance of Early Peripheral Blood Blasts Clearance Following Induction Chemotherapy for Adult Acute Myeloid Leukemia.. Blood, 2005, 106, 4631-4631.	0.6	0
72	Update on myelodysplastic syndromes: New approaches to classification and therapy. Seminars in Oncology, 2004, 31, 72-79.	0.8	7

#	ARTICLE	IF	CITATIONS
73	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML.. Blood, 2004, 104, 1814-1814.	0.6	2
74	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. Blood, 2004, 104, 3159-3159.	0.6	0
75	Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood, 2002, 99, 1085-1088.	0.6	77